Serine Threonine Protein Kinase ATR, Pipeline Review, H2 2019 - Artios Pharma Ltd, Bayer AG, IMPACT Therapeutics Inc & Pfizer Inc - ResearchAndMarkets.com

The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

According to the recently published report 'Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019'; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1.

The report 'SerineThreonine Protein Kinase ATR - Pipeline Review, H2 2019' outlays comprehensive information on the Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 8 and 3 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Overview
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • Artios Pharma Ltd
  • AstraZeneca Plc
  • Atrin Pharmaceuticals LLC
  • Bayer AG
  • Biokine Therapeutics Ltd
  • Cybrexa Inc
  • IMPACT Therapeutics Inc
  • Merck KGaA
  • Pfizer Inc
  • Repare Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Drug Profiles
  • ATRN-119 - Drug Profile
  • ATRN-212 - Drug Profile
  • AZ-20 - Drug Profile
  • BAY-1895344 - Drug Profile
  • berzosertib - Drug Profile
  • BKT-300 - Drug Profile
  • CBX-13 - Drug Profile
  • ceralasertib - Drug Profile
  • ceralasertib + olaparib - Drug Profile
  • IMP-09 - Drug Profile
  • M-1774 - Drug Profile
  • M-4344 - Drug Profile
  • RP-3500 - Drug Profile
  • Small Molecule to Inhibit ATR for Oncology - Drug Profile
  • Small Molecule to Inhibit ATR for Oncology - Drug Profile
  • Small Molecules to Inhibit ATR for Oncology - Drug Profile
  • VE-821 - Drug Profile
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Dormant Products
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Discontinued Products
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2cahk3

View source version on businesswire.com: https://www.businesswire.com/news/home/20200117005280/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900